InvestorsHub Logo
Followers 87
Posts 6693
Boards Moderated 1
Alias Born 09/18/2009

Re: None

Monday, 08/07/2023 9:21:53 AM

Monday, August 07, 2023 9:21:53 AM

Post# of 42926
I was absolutely thrilled to get the aGvHD trial news from Humanigen this morning...about 3 hours after getting a response from the ASCENT trial coordinator informing me that, "...any correspondence will be coming from Humanigen directly."

Ok, so the trial is getting started later than I expected. But it's another sign of forward progress being made by Humanigen.

And...to me, this is one of the most important developments I could have heard about. I say that because of lenzilumab's AMAZING progress in the CMML trial, where numerous conditions were restored to normal, or near normal levels in the patients, who could go on to become cured of cancer, following stem cell transplantation, where lenz could also prevent associated aGvHD.

Cured of cancer!

OUTSTANDING!!

https://s28.q4cdn.com/539885110/files/doc_news/Humanigen-Announces-First-Participant-Dosed-in-RATinG-Trial-of-Lenzilumab-for-Early-Treatment-of-Acute-Graft-Versus-Host-Disease-Foll-SP9A5.pdf

"Each parameter (blood monocytes, bone marrow blast percentage, platelet count, blood hemoglobin concentration, and spleen size) has exhibited a durable return to normal or near normal values, with statistical significance. Two of the ten participants have been in the trial for 18 months, the longest of any participants, and exhibit lasting improvement. No participants have relapsed. One participant is now a candidate for stem cell transplantation, which may lead to a potential cure in that patient."

https://medicalresearch.com/cancer-_-oncology/preach-m-trial-humanigen-study-evaluates-lenzilumab-and-azacitidine-for-cmml/